MDPI and ACS Style
Holubovska, O.; Babich, P.; Mironenko, A.; Milde, J.; Lebed, Y.; Stammer, H.; Mueller, L.; te Velthuis, A.J.W.; Margitich, V.; Goy, A.
RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial. Adv. Respir. Med. 2024, 92, 202-217.
https://doi.org/10.3390/arm92030021
AMA Style
Holubovska O, Babich P, Mironenko A, Milde J, Lebed Y, Stammer H, Mueller L, te Velthuis AJW, Margitich V, Goy A.
RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial. Advances in Respiratory Medicine. 2024; 92(3):202-217.
https://doi.org/10.3390/arm92030021
Chicago/Turabian Style
Holubovska, Olga, Pavlo Babich, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Lutz Mueller, Aartjan J. W. te Velthuis, Victor Margitich, and Andrew Goy.
2024. "RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial" Advances in Respiratory Medicine 92, no. 3: 202-217.
https://doi.org/10.3390/arm92030021